By David Gross
Somerville, MA -based Finch Therapeutics, a developer of microbiome therapeutics, is expanding nearby in Charlestown for $75 per square foot with standard 3% annual rent escalators. The deal also gives Finch a ROFR (right of first refusal) on additional space nearby on Rutherford Drive.
Finch has a $176 million deal with Takeda to develop an orally administered ulcerative colitis therapeutic. That drug is currently preclinical, but Takeda is going to be taking over the development to accelerate time to and through the clinic. Finch went public earlier this year, but is down about 1/3rd for its IPO price with a market cap of approximately $650 million.
Post a Comment
Note: Only a member of this blog may post a comment.